Abstract:
A composition comprising the extract of Psoralea corylifolia seed or effective compounds contained therein is provided to inhibit the activity of BACE-1(beta-site APP(amyloid precursor protein)-cleaving enzyme 1) mediating the formation of beta-amyloid as a main causing material of dementia, so that the composition is useful for preventing or treating neurodegenerative disease. A composition for preventing or treating neurodegenerative disease comprises the extract of Psoralea corylifolia seed, which is prepared by extracting Psoralea corylifolia seeds with C1-4 alcohol or its solution, dichloromethane, ethylacetate or a mixture thereof, or a compound selected from 7-hydroxy-3-(4-methyl-4-(4-methylpentene-3-yl)-4H-chromen-6-yl)-4H-chromen-4-one represented by the formula(1), bakuchiol, bavachromene, isobavachromene, bavachalcone, isobavachalcone, bavachinin, 7,8-dihydro-8-(4-hydrophenyl)-2,2-dimethyl-2H,6H-[1,2-b:5,4-b']dipyran-6-one isolated from the extract of Psoralea corylifolia seed.
Abstract:
A (3R)-amino-(4R)-aryl piperidine compound is provided to inhibit generation of beta-amyloid proteins damaging neurons by inhibiting the activity of beta-secretase(BACE), thereby being effectively used for preventing or treating Alzheimer's disease. A (3R)-amino-(4R)-aryl piperidine compound is represented by a formula(I), wherein R^1 is -(CH)n-Ar, -(CH)n-CO-Ar, -(CH)n-SO2-Ar, or -(CH)n-CO-NH-Ar(where n is an integer from 0 to 3, Ar is a group represented by the structural formula(1) or (2); R^2 is H or halogen substituted or unsubstituted phenyl; and R^3 is H, -CO-R^6, -SO2-R^7, -CO-(CH2)m-R^8, -CO-NH-(CH2)m-R^9, -COO-(CH2)m-R^10, -CO-N(R^11)-(CH2)m-COO-R^12, -CO-NH-C(R^13))(R^14)-(CH2)m-COO-R^15 or -CO-C(R^16)(R^17)-NH-COO-(CH2)m-R^18(where each R^6 to R^18 is H, halogen, hydroxy or C1-6 alkyl which may be substituted or unsubstituted by C1-3 alkoxy, C1-3 alkylsulfonyl or the Ar same as defined above the R^1 and m is an integer from 0 to 2). In the structural formula(1) or (2), each Y^1 and Y^2 is independently H, phenyl, phenoxy, C1-3 alkoxy or -CO-N(R^4)R^5(wherein each R^4 and R^5 is independently C1-3 alkyl). A pharmaceutical composition for preventing or treating Alzheimer's disease or Down's syndrome comprises the compound of the formula(1) or a pharmaceutically acceptable salt thereof as an effective ingredient.
Abstract:
본 발명은 하기 화학식 1로 표시되는 신규 치환된-1H-퀴나졸린-2,4-디온 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물에 관한 것으로, 본 발명의 신규 치환된-1H-퀴나졸린-2,4-디온 유도체는 세로토닌 5-HT6 수용체와의 결합력이 우수하고, 다른 수용체들과 비교할 때 5-HT6 수용체와의 선택성이 뛰어나고, 세포 내 세로토닌(5-HT)에 의한 cAMP의 농도 증가를 억제할 뿐만 아니라, 아포몰핀(2 ㎎/㎏, ip)으로 유도된 랫트의 행동 과다를 억제하는 효과가 있어 5-HT6 수용체와 관련된 중추신경계 질환에 유용하게 사용될 수 있다.
Abstract:
A compound having a BACE-1 inhibitory effect and an extract obtained from bark of grapevine and containing the same compound are provided to obtain a pharmaceutical composition or health-aid food for preventing or treating neurodegenerative diseases. A compound having a BACE-1 inhibitory effect is represented by the following formula 1. The compound represented by formula 1 is obtained through an extraction process using an organic solvent selected from the group consisting of C1-C4 alcohols or aqueous solution thereof, dichloromethane, ethyl acetate and a mixture thereof. Particularly, the compound represented by formula 1 is obtained by extracting bark of grapevine with the organic solvent, and by further extracting the extract with an organic solvent selected from the group consisting of butanol, dichloromethane and ethyl acetate.
Abstract:
A novel substituted-1,1-dioxo-benzo[1,2,4]thiadiazin-3-one is provided to improve binding ability with serotonin 5-HT6 receptor and selectivity to 5-HT6, inhibit increase of cAMP(cyclic AMP) concentration caused by serotonin(5-HT) in cells, and show no rotarod function disorder at effective dosage. A novel substituted-1,1-dioxo-benzo[1,2,4]thiadiazin-3-one represented by the formula(1) and its pharmaceutically acceptable salt are provided, wherein R^1 is hydrogen, C1-C10 alkyl, C3-C10 aryl, C3-C7 cycloalkyl, arylalkyl, heteroaryl or heteroarylalkyl; R^2 is hydrogen, C1-C10 alkyl, C3-C10 aryl, heteroaryl, aralkyl, heteroarylalkyl, amino or cyclic amino; R^3, R^4 and R^5 are each independently hydrogen, halogen, amino, cyclic amino, nitro, cyano, C1-C10 alkyl, haloalkyl, C1-C7 alkoxy, haloalkoxy or piperazinyl or N-methyl piperazinyl; and Z is mono-, bi- or tri-cyclic amine containing 1-3 nitrogen atoms and 5-12 carbons in its ring. A preparation method of the substituted-1,1-dioxo-benzo[1,2,4]thiadiazin-3-one represented by the formula(1) comprises the steps of: (a) reacting compound 2 with amine in the presence of base to prepare an intermediate I; (b) cyclizing the intermediate I to prepare an intermediate II; (c) substituting the intermediate II in the presence of base to prepare an intermediate III; and (d) nucleophilically substituting the intermediate III and amine according to the reaction formula(1).
Abstract:
An external skin composition for skin whitening comprising the extract of Cassia tora or emodin isolated therefrom is provided to inhibit maturation and differentiation of melanin cells by inhibiting activity of c-Kit participating in signal transfer related to promotion of melanin synthesis caused by ultraviolet rays. An external skin composition for skin whitening comprises the extract of Cassia tora which is prepared by extracting Cassia tora with water, C1-C4 alcohol, mixed solvents thereof or chloroform, or emodin extracted from the Cassia tora extract which is obtained by extracting Cassia tora with methanol, fractioning the methanol extract with hexane and chloroform sequentially to obtain a chloroform fraction, and subjecting the chloroform fraction to the column chromatography using mixed solvents containing chloroform and methanol in a volume ratio of 20:1 to 5:1, and is a pharmaceutical composition for preventing and treating hemochromatosis or a cosmetic composition for skin whitening.
Abstract:
본 발명은 5-HT6 수용체 길항제로 작용하는 N -치환된-1 H -퀴놀린-2,4-디온 화합물, 이의 제조방법 및 이를 함유하는 중추신경계 질환 치료용 약학적 조성물에 관한 것으로, 본 발명의 N -치환된-1 H -퀴놀린-2,4-디온 화합물은 세로토닌 5-HT6 수용체와의 결합력이 우수하고, 다른 수용체들과 비교할 때 5-HT6 수용체와의 선택성이 뛰어나고, 세포 내 세로토닌(5-HT)에 의한 cAMP의 농도 증가를 억제할 뿐만 아니라, 메트암페타민(2 ㎎/㎏, ip)으로 유도된 랫트의 행동과다를 억제하는 효과가 있어 5-HT6 수용체와 관련된 중추신경계 질환에 유용하게 사용될 수 있다. 5-HT6 수용체 길항제, 중추신경계 질병
Abstract:
본 발명은 다음 화학식 1로 표시되는 후퍼진(huperzine) B 유도체와 이의 제조방법에 관한 것으로서, 더욱 상세하게는 다음 화학식 2로 표시되는 카르복실산 화합물을 출발물질로 사용하고, C5 위치의 카르복실기를 아민화 및 N -알켄일화하여 다음 화학식 4로 표시되는 화합물을 반응 중간체로 합성한 후에, 이 중간체 화합물을 복분해반응(Ring Closing Metathesis, RCM)한 후에 메틸보호기를 제거하는 일련의 제조과정을 거쳐 합성하게 되는, 다음 화학식 1로 표시되는 후퍼진 B 유도체와 이의 제조방법에 관한 것이다. 본 발명에 따른 상기 화학식 1로 표시되는 화합물은 치매치료 효과가 있는 것으로 잘 알려져 있는 후퍼진 B 화합물의 유도체로서 화합물 그 자체의 의약적 활성이 기대된다.
Abstract:
본 발명은 우수한 항산화 활성을 갖는 페닐아미딘 유도체 및 이를 포함하는 약학적 조성물에 관한 것으로, 더욱 구체적으로 하기 화학식 1로 표시되는 페닐아미딘 유도체는 종래 항산화제 화합물에 비해 항산화 활성이 우수할 뿐만 아니라 독성이 적어 노화 방지제, 암, 당뇨병 및 간질의 치료제, 그리고 치매, 파킨스씨 병, 뇌졸중 및 헌팅톤의 신경퇴행성 질환 치료제로 유용하게 사용될 수 있다. 화학식 1
Abstract:
본 발명은 하기 화학식 1의 3-아릴티오-4-하이드록시퀴놀린-2(1H)-온 유도체 및 그 제조방법에 관한 것이다. 본 발명의 화합물은 간질, 알츠하이머병, 헌팅톤병 및 파킨슨병을 포함하는 만성 신경퇴행성 질환의 예방 및 치료에 유용하다. 또한 본 발명의 화합물은 뇌졸증, 저혈당증, 국소빈혈, 심장박동정지, 외상과 같은 빈혈이나 저산소증의 결과로서 야기되는 중추신경계의 손상을 줄이는데 유용하다. 또한, 본 발명의 화합물은 항경련제, 진통제, 항우울증 치료제, 항불안 치료제 및 항정신분열증 치료제로 사용된다.